Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 7.9% in October

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 3,670,000 shares, a growth of 7.9% from the October 15th total of 3,400,000 shares. Based on an average trading volume of 443,400 shares, the days-to-cover ratio is currently 8.3 days. Approximately 6.4% of the company’s stock are short sold.

Aldeyra Therapeutics Stock Down 1.4 %

Aldeyra Therapeutics stock opened at $4.21 on Monday. Aldeyra Therapeutics has a one year low of $2.43 and a one year high of $6.55. The business’s fifty day moving average is $5.45 and its 200 day moving average is $4.60. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). Equities analysts anticipate that Aldeyra Therapeutics will post -0.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of large investors have recently added to or reduced their stakes in ALDX. King Wealth Management Group lifted its holdings in shares of Aldeyra Therapeutics by 24.5% during the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 2,700 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Aldeyra Therapeutics by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 2,729 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Aldeyra Therapeutics by 7.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 3,446 shares during the last quarter. Providence Wealth Advisors LLC grew its stake in shares of Aldeyra Therapeutics by 16.3% during the 2nd quarter. Providence Wealth Advisors LLC now owns 25,000 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 3,500 shares during the period. Finally, Laidlaw Wealth Management LLC increased its position in shares of Aldeyra Therapeutics by 32.6% during the 2nd quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 4,150 shares during the last quarter. Institutional investors own 59.71% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.